Genetic variant associated with aggressive not ind... [Cancer Biol Ther. 2010] - PubMed result

Cancer Biol Ther. 2010 Jun 22;9(12). [Epub ahead of print]

Genetic variant associated with aggressive not indolent prostate cancer.
Kirkland CT, Price DK, Figg WD.

Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

Abstract
Genome wide association studies have identified over two dozen single nucleotide polymorphisms (SNPs) that are associated with an increased risk of developing prostate cancer. Of note, all of these designs were case-control studies. In order to better differentiate between aggressive and indolent prostate cancer, Xu et al. performed the first case-case study design where 4,829 patients with aggressive prostate cancer were compared to 12,205 patients with less aggressive disease as defined by Gleason score. Their work, published in a recent issue of Proceedings of the National Academy of Sciences, identified a genetic variant, rs4054823, which significantly distinguished between the two natures of prostate tumors. Results indicated a 25% increased likelihood of developing aggressive prostate cancer with the TT genotype (p = 2.1 x 10(-6)). While one biomarker alone does not warrant clinical change, this finding encourages future research to utilize a case-case genotyping methodology in order to effectively characterize risk of aggressive prostate cancer. Delineation would benefit clinicians in their diagnosis and treatment and ultimately would reduce the number of men who are overtreated from PSA-based screening.


Genetic variant associated with aggressive not ind... [Cancer Biol Ther. 2010] - PubMed result